A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

被引:64
|
作者
Singh, Dig Vijay [1 ]
Mete, Uttam Kumar [1 ]
Mandal, Arup Kumar [1 ]
Singh, Shrawan Kumar [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Urol, Chandigarh 160012, India
关键词
Tamsulosin; Tadalafil; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Erectile Dysfunction; Medical Therapy; COMBINED ORAL-THERAPY; ERECTILE DYSFUNCTION; PHOSPHODIESTERASE-5; INHIBITORS; INTEGRATED APPROACH; SILDENAFIL CITRATE; SEXUAL DYSFUNCTION; ALPHA-BLOCKERS; MEN; EPIDEMIOLOGY; ALFUZOSIN;
D O I
10.1111/jsm.12357
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age. Aim To evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH. Methods In this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg/day alone (Group A), 44 patients received tadalafil 10 mg/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment. Main Outcome Measures There were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event. Results A significant improvement in IPSS score was observed in all the 3 groups A, B, and C (-50.90%, P<0.05; -33.50%, P<0.05; and -53.90%, P<0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P<0.05; +45.96%, P<0.05; and +60.23%, P<0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P<0.05; 29.78%, P<0.05; and 37.04%, P<0.05) and (-60.90%, P<0.05; -49.45%, P<0.05; and -62.97%, P<0.05, respectively). The QoL scores improved significantly (-73.35%, P<0.05; -70.26%, P<0.05; and -79.65%, P<0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events. Conclusions In patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone.
引用
收藏
页码:187 / 196
页数:10
相关论文
共 50 条
  • [21] Efficacy and Safety of Combined Oral Therapy with Tadalafil and Alfuzosin: An Integrated Approach to the Management of Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction. Preliminary Report
    Liguori, Giovanni
    Trombetta, Carlo
    De Giorgi, Gioacchino
    Pomara, Giorgio
    De Giorgi, Giuseppe
    Vecchio, Daniele
    Ocello, Giuseppe
    Ollandini, Giangiacomo
    Bucci, Stefano
    Belgrano, Emanuele
    JOURNAL OF SEXUAL MEDICINE, 2009, 6 (02) : 544 - 552
  • [22] Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
    Sun, Kai
    Sun, Fengze
    Yao, Huibao
    Zhang, Dongxu
    Wu, Gang
    Wang, Tianqi
    Wang, Jipeng
    Wu, JiTao
    AMERICAN JOURNAL OF MENS HEALTH, 2020, 14 (06)
  • [23] A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF TAMSULOSIN AND SILODOSIN IN TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
    Yaraguppi, Amulya F.
    Ramesh, H.
    Jadav, Ravikumar
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (02): : 146 - 151
  • [24] Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial
    Karami, Hossein
    Hassanzadeh-Hadad, Amin
    Fallah-Karkan, Morteza
    UROLOGY JOURNAL, 2016, 13 (06) : 2920 - 2926
  • [25] Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia
    Rahardjo, Djoko
    Soebadi, Doddy M.
    Sugandi, Suwandi
    Birowo, Ponco
    Djati, Wahjoe
    Wahyudi, Irfan
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (11) : 1405 - 1409
  • [26] Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Gotoh, Daisuke
    Torimoto, Kazumasa
    Morizawa, Yosuke
    Hori, Shunta
    Nakai, Yasushi
    Miyake, Makito
    Fujimoto, Kiyohide
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [27] Comparison between combination of tamsulosin and Pentoxifylline versus tamsulosin alone in the treatment of lower urinary tract symptoms due to benign prostate hyperplasia: A preliminary study
    Shirazi, Mehdi
    Dehghanmanshadi, Alireza
    Sadr, Soroush
    Jahanabadi, Zahra
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2024, 16 (01)
  • [28] Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
    AbdelRazek, Mostafa
    Abolyosr, Ahmad
    Mhammed, Omar
    Fathi, Atef
    Talaat, Mohammed
    Hassan, Ahmed
    WORLD JOURNAL OF UROLOGY, 2022, 40 (08) : 2063 - 2070
  • [29] Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
    Dimitropoulos, Konstantinos
    Gravas, Stavros
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1707 - 1716
  • [30] Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes
    Tawfik, Ahmed
    Abo-Elenen, Mohammed
    Gaber, Mohammed
    El-Abd, Ahmed
    Zoeir, Ahmed
    Saad, Sayed
    Sultan, Intessar
    Ghoneim, Ayman
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)